What's Happening in Neurology® Neuroimmunology & Neuroinflammation

Objective

To evaluate the use of CSF neurofilament light chain (NfL) measurements in clinical practice as well as their effect on treatment strategies and outcomes in patients with MS.

Methods

This was an observational cohort study of patients with MS who had a CSF NfL measurement between December 2015 and July 2018 as part of their routine clinical care. Treatment strategies were classified as “No Treatment/No Escalation” (no treatment or no escalation of treatment) or “Treatment/Escalation” (first-line injectable/oral disease-modifying therapies (DMTs), highly active DMTs, or treatment escalation). Change in Expanded Disability Status Scale (EDSS) scores was evaluated after the 1-year follow-up.

Results

Of 203 patients with MS, 117 (58%) had relapsing-remitting MS. Disease activity was most frequently indicated by elevated CSF NfL (n = 85), followed by clinical (n = 81) and MRI activity (n = 65). CSF NfL measurements were independently associated with clinical (p = 0.02) and MRI activity (p < 0.001). Of those with elevated CSF NfL as the only evidence of disease activity (n = 22), 77% had progressive MS (PMS). In patients with PMS, 17 (20%) had elevated CSF NfL as the sole indicator of disease activity. Elevated CSF NfL resulted more frequently in Treatment/Escalation than normal CSF NfL (p < 0.001). Median EDSS change at follow-up was similar between patients receiving No Treatment/No Escalation and Treatment/Escalation decisions (p = 0.81).

Conclusions

CSF NfL measurements informed treatment strategies, alongside clinical and MRI measures. CSF NfL levels were the only indicator of disease activity in a subset of patients, which was more pronounced in patients with PMS. Elevated CSF NfL was associated with more Treatment/Escalation strategies, which had an impact on EDSS outcomes at 1 year.

NPub.org/NN/9608a

Objective

To explore the hypothesis that serum neurofilament light chain (sNfL) indicative of neuroaxonal damage may improve precise disease profiling with regard to cognition and neuropsychiatric symptoms, we analyzed potential associations of sNfL levels with cognitive test scores, fatigue, depression, and anxiety.

Methods

Patients with relapsing-remitting and secondary progressive MS (SPMS) underwent an elaborated assessment including MRI, various cognitive tests, and patient-reported outcomes. We determined sNfL levels by single molecule array (Simoa) assay. Relationships between sNfL, cognition, neuropsychiatric symptoms, and demographical data were analyzed using correlations, group comparisons, and regressions.

Results

In 45 clinically stable patients with MS (Expanded Disability Status Scale = 2.73 ± 1.12, disease duration = 10.03 ± 7.49 years), 40.0% were cognitively impaired. Mean sNfL levels were 16.02 ± 10.39 pg/mL, with higher levels in the SPMS subgroup (p = 0.038). sNfL levels did reliably link neither with the investigated cognitive and affective parameters nor with fatigue levels. The only relationship found in a small subgroup of patients with SPMS (n = 7) with visuospatial learning (r = −0.950, p = 0.001) and memory (r = −0.813; p = 0.026) disappeared when further controlling for age, educational level, and sex.

Conclusions

In patients with stable MS at less advanced disease stages, sNfL did not convincingly relate to cognitive performance, fatigue, depression, or anxiety and thus may not serve as a surrogate biomarker for neuropsychological status in such populations.

NPub.org/NN/9608b

As of December 22, 2020

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease

P. Waters, M. Woodhall, K.C. O'Connor, et al. 2015;2:e89. doi.org/10.1212/NXI.0000000000000089

Aquaporin-4 autoimmunity

A. Zekeridou, V.A. Lennon 2015;2:e110. doi.org/10.1212/NXI.0000000000000110

Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors

A. Vogrig, M. Fouret, B. Joubert, et al. 2019;6:604. doi.org/10.1212/NXI.0000000000000604

Guillain-Barré syndrome related to COVID-19 infection

P. Alberti, S. Beretta, M. Piatti, et al. 2020;7:741. doi.org/10.1212/NXI.0000000000000741

Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?

H. Stiebel-Kalish, M.A. Hellmann, M. Mimouni, et al. 2019;6:e572. doi.org/10.1212/NXI.0000000000000572